After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer

Blueprint Medicines Corp BPMC announced proof-of-concept data from the Phase 1/2 SYMPHONY trial of BLU-945 for advanced EGFR-mutant non-small cell lung cancer (NSCLC).

• The data were shared at the American Association for Cancer Research (AACR) Annual Meeting 2022.
• The early readout from the phase 1/2 Symphony trial shows the first safety and clinical activity data.
• Results from the higher dose group hint at tumor shrinkage too. One patient treated with 400 mg once daily experienced a partial response as of the March 9 cut-off date.
• As for safety, common adverse events included nausea, headache, difficulty breathing and vomiting, among others. 
• Blueprint did observe one incident of dose-limiting toxicity in a patient who experienced high levels of an enzyme called transaminases that can point to problems with the liver. 
• The dose was interrupted, and the patient improved. Blueprint said that there were no study discontinuations.
• Blueprint will initiate an additional cohort in the Symphony trial combining BLU-945 with AstraZeneca Plc's AZN Tagrisso (osimertinib) following disease progression on osimertinib.
• The company announced a clinical supply agreement with AstraZeneca for work on the study and the early-stage Harmony program for BLU-701.
• Price Action: BPMC shares traded lower by 3.46% at $67.18 on the last check Monday.